Last Price$184.9(2.1%)
Market Cap$33.7B
2.5%
Peers median - 0.4%
13.7%
Peers median - 18.7%
21.7%
Peers median - 43.2%
8.8%
Peers median - 11.7%
Competing with IQV
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$33.7B | 6.1 | $301.3 63.0% undervalued | (26.5%) | $15.4B | $2,114.0M | 2.5% | 13.7% | 31.4% | 8.8% | 21.7% | |
$201.0B | 6.5 | $602.4 15.0% undervalued | (9.7%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 8.3% | 63.1% | |
$151.3B | 6.1 | $167.0 18.8% overvalued | (19.4%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$36.5B | 7.4 | $103.7 17.9% overvalued | (11.0%) | $6,533.0M | $1,409.0M | (3.0%) | 21.6% | 65.9% | 14.7% | 55.8% | |
$36.1B | 7.2 | $219.3 49.8% overvalued | (23.5%) | $3,897.5M | $798.1M | 6.5% | 20.5% | 61.1% | 49.4% | 6.3% | |
$27.1B | 7.0 | $869.6 31.5% overvalued | (1.4%) | $3,872.4M | $864.4M | 2.2% | 22.3% | 59.1% | 49.8% | (1,587.1%) | |
$22.2B | 6.5 | $236.1 36.5% overvalued | 7.2% | $2,958.4M | $619.6M | 0.1% | 20.9% | 58.2% | 19.4% | 0.0% | |
$21.2B | 6.1 | $621.0 144.4% undervalued | 17.1% | $13.0B | $1,095.9M | 0.8% | 8.4% | 26.9% | 6.0% | 24.1% | |
$19.6B | 6.0 | $369.8 109.0% undervalued | 44.2% | $9,872.0M | $909.0M | 6.7% | 9.2% | 32.4% | 8.8% | 102.2% | |
$18.5B | 6.0 | $70.9 50.4% overvalued | 58.6% | $1,532.0M | ($33.2M) | 54.9% | (2.2%) | 57.7% | (44.9%) | 54.2% | |
$13.9B | 6.2 | $147.2 74.8% undervalued | (37.1%) | $4,372.0M | $696.0M | (2.9%) | 15.9% | 65.4% | 34.6% | 93.8% |
Compare IQV Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
IQVIA Holdings Inc.IQV
2.2x
2.8%
2.4%
8.9%
Median Peer Set
6.4x
(1.7%)
(7.2%)
15.2%
Agilent Technologies, Inc.A
5.9x
(4.7%)
5.0%
19.8%
Quest Diagnostics IncorporatedDGX
2.6x
(6.4%)
(6.5%)
9.2%
Danaher CorporationDHR
6.9x
(0.1%)
(17.9%)
16.3%
IDEXX Laboratories, Inc.IDXX
9.2x
8.7%
25.2%
23.1%
Illumina, Inc.ILMN
3.5x
(2.9%)
4.6%
(28.0%)
Laboratory Corporation of America HoldingsLH
N/A
(18.3%)
(65.8%)
3.4%
Mettler-Toledo International Inc.MTD
7.5x
2.2%
12.7%
22.3%
Natera, Inc.NTRA
11.8x
32.0%
(32.1%)
(40.2%)
Thermo Fisher Scientific Inc.TMO
5.3x
(4.6%)
(12.4%)
14.0%
Waters CorporationWAT
7.4x
(0.5%)
(7.9%)
21.7%
Compare IQV Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does IQVIA Holdings Inc. (IQV) revenue growth compare to peers and the industry?
IQVIA Holdings Inc. (IQV) revenue growth is 2.5%, compared to the peers' median of 0.4%.
2. How does IQVIA Holdings Inc. (IQV) Free Cash Flow (FCF) margin compare to peers and the industry?
IQVIA Holdings Inc. (IQV) FCF margin is 13.7%, compared to the peers' median of 18.7%.
3. How does IQVIA Holdings Inc. (IQV) Total Debt to Equity ratio compare to peers and the industry?
IQVIA Holdings Inc. (IQV) Total Debt to Equity ratio is 21.7%, compared to the peers' median of 43.2%.
4. How does IQVIA Holdings Inc. (IQV) ROIC (Return on Invested Capital) compare to peers and the industry?
IQVIA Holdings Inc. (IQV) ROIC is 8.8%, compared to the peers' median of 11.7%.